CD248 and glioblastoma: First, CD248 expression levels are heterogeneous within distinct tumor microenvironments, with elevated expression observed in tumors rich in CAFs and vascularization, such as in GBM, KIRC, and LIHC (Zhang et al., 2021; Carson-Walter et al., 2009).